The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
Pfizer is likely to show GSK significant competition
Construction will begin this year with the new capacity anticipated by 2025
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
The development and deployment of effective vaccines can help to mitigate the impact of pandemics, and we must prioritize research efforts to achieve this objective
One thousand times more soluble than L-cystine at neutral pH
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
Subscribe To Our Newsletter & Stay Updated
